Detection and treatment of LRP4-associated neurotransmission disorders
US9244082B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 20, 2012 |
| Grant date | Jan 26, 2016 |
| Priority date | — |
| Expiry date | Apr 20, 2032 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/38
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.